These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 26063503

  • 1. A Randomized Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Clopidogrel in Three Different CYP2C19 Genotype Groups of Healthy Japanese Subjects.
    Kobayashi M, Kajiwara M, Hasegawa S.
    J Atheroscler Thromb; 2015; 22(11):1186-96. PubMed ID: 26063503
    [Abstract] [Full Text] [Related]

  • 2. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Aug; 90(2):287-95. PubMed ID: 21716274
    [Abstract] [Full Text] [Related]

  • 3. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
    Gurbel PA, Bliden KP, Logan DK, Kereiakes DJ, Lasseter KC, White A, Angiolillo DJ, Nolin TD, Maa JF, Bailey WL, Jakubowski JA, Ojeh CK, Jeong YH, Tantry US, Baker BA.
    J Am Coll Cardiol; 2013 Aug 06; 62(6):505-12. PubMed ID: 23602770
    [Abstract] [Full Text] [Related]

  • 4. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H, Isshiki T, Kimura T, Yokoi H, Nanto S, Takayama M, Kitagawa K, Nishikawa M, Miyazaki S, Ikeda Y, Nakamura M, Tanaka Y, Saito S.
    J Cardiol; 2016 Jul 06; 68(1):29-36. PubMed ID: 26521100
    [Abstract] [Full Text] [Related]

  • 5. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA, Bergmeijer TO, Tantry US, ten Berg JM, Angiolillo DJ, James S, Lindahl TL, Svensson P, Jakubowski JA, Brown PB, Duvvuru S, Sundseth S, Walker JR, Small D, Moser BA, Winters KJ, Erlinge D.
    Thromb Haemost; 2014 Sep 02; 112(3):589-97. PubMed ID: 25008027
    [Abstract] [Full Text] [Related]

  • 6. Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel.
    Kitazono T, Ikeda Y, Nishikawa M, Yoshiba S, Abe K, Ogawa A.
    J Thromb Thrombolysis; 2018 Nov 02; 46(4):488-495. PubMed ID: 30074128
    [Abstract] [Full Text] [Related]

  • 7. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
    Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Lampa M, Brooks JK, Barnard MR, Michelson AD.
    J Am Coll Cardiol; 2013 Feb 26; 61(8):872-9. PubMed ID: 23333143
    [Abstract] [Full Text] [Related]

  • 8. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y12 inhibitor.
    Zhang Y, Zhu X, Zhan Y, Li X, Liu C, Zhu Y, Zhang H, Wei H, Xia Y, Sun H, Liu Y, Lai X, Gong Y, Liu X, Li Y, Ding Y, Zhong D.
    Br J Clin Pharmacol; 2020 Sep 26; 86(9):1860-1874. PubMed ID: 32267573
    [Abstract] [Full Text] [Related]

  • 9. Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation.
    Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, Hoshino K, Aoki T, Nishimura Y, Tamaru S, Ito M, Nishikawa M, McLordd Group.
    Circ J; 2013 Sep 26; 77(6):1436-44. PubMed ID: 23470885
    [Abstract] [Full Text] [Related]

  • 10. Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.
    González A, Moniche F, Cayuela A, García-Lozano JR, Torrecillas F, Escudero-Martínez I, Gonzalez-Marcos JR, Mayol A, Montaner J.
    Eur J Vasc Endovasc Surg; 2016 Feb 26; 51(2):175-86. PubMed ID: 26526111
    [Abstract] [Full Text] [Related]

  • 11. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA.
    Circ Cardiovasc Genet; 2010 Dec 26; 3(6):556-66. PubMed ID: 21079055
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants.
    Kelly RP, Close SL, Farid NA, Winters KJ, Shen L, Natanegara F, Jakubowski JA, Ho M, Walker JR, Small DS.
    Br J Clin Pharmacol; 2012 Jan 26; 73(1):93-105. PubMed ID: 21689142
    [Abstract] [Full Text] [Related]

  • 14. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel.
    Pedersen RS, Nielsen F, Stage TB, Vinholt PJ, el Achwah AB, Damkier P, Brosen K.
    Clin Exp Pharmacol Physiol; 2014 Nov 26; 41(11):870-8. PubMed ID: 25115434
    [Abstract] [Full Text] [Related]

  • 15. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS.
    JAMA; 2011 Nov 23; 306(20):2221-8. PubMed ID: 22088980
    [Abstract] [Full Text] [Related]

  • 16. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.
    Kim KA, Park PW, Hong SJ, Park JY.
    Clin Pharmacol Ther; 2008 Aug 23; 84(2):236-42. PubMed ID: 18323861
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness of clopidogrel dose escalation to normalize active metabolite exposure and antiplatelet effects in CYP2C19 poor metabolizers.
    Horenstein RB, Madabushi R, Zineh I, Yerges-Armstrong LM, Peer CJ, Schuck RN, Figg WD, Shuldiner AR, Pacanowski MA.
    J Clin Pharmacol; 2014 Aug 23; 54(8):865-73. PubMed ID: 24710841
    [Abstract] [Full Text] [Related]

  • 18. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J.
    Gene; 2015 Mar 10; 558(2):200-7. PubMed ID: 25542807
    [Abstract] [Full Text] [Related]

  • 19. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V, Azizi M, Gaussem P.
    Arch Cardiovasc Dis; 2013 Dec 10; 106(12):661-71. PubMed ID: 24246616
    [Abstract] [Full Text] [Related]

  • 20. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N, Yin S, Sun Z, Xu X, Qin J.
    Scand J Clin Lab Invest; 2015 May 10; 75(3):223-9. PubMed ID: 25594796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.